These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22283691)

  • 1. Contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-7.
    Lichtenberg FR
    Pharmacoeconomics; 2012 Mar; 30(3):197-211. PubMed ID: 22283691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical innovation and the longevity of Australians: a first look.
    Lichtenberg FR; Duflos G
    Adv Health Econ Health Serv Res; 2008; 19():95-117. PubMed ID: 19548515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009.
    Lichtenberg FR
    Econ Hum Biol; 2014 Mar; 13():107-27. PubMed ID: 23664114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010.
    Lichtenberg FR; Tatar M; Çalışkan Z
    Health Policy; 2014 Sep; 117(3):361-73. PubMed ID: 24996837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012.
    Lichtenberg FR
    Eur J Health Econ; 2016 Sep; 17(7):833-54. PubMed ID: 26342826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries.
    Lichtenberg FR
    Econ Hum Biol; 2022 Aug; 46():101124. PubMed ID: 35344806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data.
    Lichtenberg FR; Grootendorst P; Van Audenrode M; Latremouille-Viau D; Lefebvre P
    Value Health; 2009 Sep; 12(6):847-56. PubMed ID: 19490554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files.
    Lichtenberg FR
    Forum Health Econ Policy; 2013 Jan; 16(1):1-33. PubMed ID: 31419866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.
    Lichtenberg FR
    Int J Health Care Finance Econ; 2005 Mar; 5(1):47-73. PubMed ID: 15714263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998-2017.
    Lichtenberg FR
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):476-477. PubMed ID: 33412958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing life expectancy in Germany: quantitative contributions from changes in age- and disease-specific mortality.
    Klenk J; Rapp K; Büchele G; Keil U; Weiland SK
    Eur J Public Health; 2007 Dec; 17(6):587-92. PubMed ID: 17403787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence.
    Hostenkamp G; Lichtenberg FR
    Soc Sci Med; 2015 Apr; 130():162-71. PubMed ID: 25703669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fall of marital fertility in nineteenth-century France: exemplar or exception? (Part I).
    Wrigley EA
    Eur J Popul; 1985 Jan; 1(1):31-60. PubMed ID: 12159012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011.
    Lichtenberg FR
    Int J Health Econ Manag; 2015 Sep; 15(3):339-359. PubMed ID: 27878681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of new companies for drug discovery: origins of a decade of new drugs.
    Kneller R
    Nat Rev Drug Discov; 2010 Nov; 9(11):867-82. PubMed ID: 21031002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007.
    Lichtenberg FR
    Eur J Health Econ; 2013 Feb; 14(1):41-56. PubMed ID: 21953319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outlook for the next 5 years in drug innovation.
    Berggren R; Møller M; Moss R; Poda P; Smietana K
    Nat Rev Drug Discov; 2012 Jun; 11(6):435-6. PubMed ID: 22653208
    [No Abstract]   [Full Text] [Related]  

  • 18. Adolescent experience predicts longevity: evidence from historical epidemiology.
    Falconi A; Gemmill A; Dahl RE; Catalano R
    J Dev Orig Health Dis; 2014 Jun; 5(3):171-7. PubMed ID: 24901655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010.
    Lichtenberg FR
    Appl Health Econ Health Policy; 2015 Apr; 13(2):207-22. PubMed ID: 25564200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quality of medical care, behavioral risk factors, and longevity growth.
    Lichtenberg FR
    Int J Health Care Finance Econ; 2011 Mar; 11(1):1-34. PubMed ID: 21188512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.